Effect on quality of life in patients with pityriasis rosea: Is it associated with rash severity?

International Journal of Dermatology

Volumn 44, Issue 5, 2005, Pages 372-377

  Chuh, Antonio A T ^a,b   Chan, Henry H L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Bonham Surgery   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACNE VULGARIS; ADOLESCENT; ADULT; AGE; ARTICLE; ATOPIC DERMATITIS; CHINESE; CONTROLLED STUDY; CORRELATION FUNCTION; DERMATOLOGY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PITYRIASIS ROSEA; QUALITY OF LIFE; RASH; RELIABILITY; SCORING SYSTEM; SKIN INFECTION; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; VALIDATION PROCESS;

ACNE VULGARIS; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DERMATITIS, ATOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PITYRIASIS ROSEA; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 18844404173     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2005.02007.x     Document Type: Article

References (21)

1. Chuh AA, Chin SS, Peiris JS. Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: a prospective case control study. Acta Derm Venereol 2001; 81: 289-290.
2. Watanabe T, Sugaya M, Nakamura K, et al. Human herpesvirus 7 and pityriasis rosea. J Invest Dermatol 1999; 113: 288-289.
3. Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in pityriasis rosea. Lancet 1997; 349: 1367-1368.
4. Harlow D, Poyner T, Finlay AY, et al. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000; 143: 979-982.
5. du Vivier A. Pityriasis rosea and lichen planus. In: Dermatology in Practice. Gower: Medical Publishing, 1992: 64-65.
6. Vigh G. Observations on pityriasis rosea patients. Z Hautkr 1983; 58: 1268-1272.
7. Sharma PK, Yadav TP, Gautam RK, et al. Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 2000; 42: 241-244.
8. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
9. Finlay AY. Measures of the effect of severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996; 7: 149-154.
10. Harris A, Burge SM, Dykes PJ, et al. Handicap in Darier's disease and Hailey-Hailey disease. Br J Dermatol 1996; 135: 959-963.
11. Blackford S, Finlay AY, Roberts DL. Quality of life in Behcets' syndrome: 335 patients surveyed. Br J Dermatol 1997; 136: 293.
12. Chuh AA, Au TS. Pityriasis rosea - a review of the specific treatments. Proc R Coll Physicians Edinb 2001; 31: 203-207.
13. Leenutaphong V, Jiamton S. UVB phototherapy for pityriasis rosea: a bilateral comparison study. J Am Acad Dermatol 1995; 33: 996-999.
14. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993; 186: 23-31.
15. Burke BM, Cunliffe WJ. The assessment of acne vulgaris - the Leeds technique. Br J Dermatol 1984; 111: 83-92.
16. Williams HC, Burney PG, Pembroke AC, et al. Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. U.K. Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol 1996; 135: 12-17.
17. Chuh AA, Chan HH. Prospective case-control study of chlamydia, legionella and mycoplasma infections in patients with pityriasis rosea. Eur J Dermatol 2002; 12: 170-173.
18. Chuh AAT. Collarette scaling in pityriasis rosea demonstrated by digital epiluminescence dermatoscopy. Australas J Dermatol 2001; 42: 288-290.
19. Chuh AA, Peiris JS. Lack of evidence of active human herpesvirus 7 (HHV-7) infection in three cases of pityriasis rosea in children. Pediatr Dermatol 2001; 18: 381-383.
20. Messenger AG, Knox EG, Summerly R, et al. Case clustering in pityriasis rosea: support for role of an infective agent. Br Med J (Clin Res Ed) 1982; 284: 371-373.
21. Bigby MA. Remarkable result of a double-masked, placebo-controlled trial of erythromycin in the treatment of pityriasis rosea. Arch Dermatol 2000; 136: 775-776.